Key Findings:  These data suggest that the body’s own endocannabinoid 2-AG negatively modulates the inflammatory milieu of cancer cells in vitro (via CB1 and CB2 activation) thus potentially increasing proliferation, while AM281 (a CB1 inverse agonist) decreased cancer proliferation.
Type of Study:  Laboratory Study
Study Result:  Inconclusive
Study Location(s):  Italy
Year of Pub:  2015
Cannabinoids Studied:  AM-x Synthetic Cannabinoids, 2-Arachidonoyl Glycerol (2-AG)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2
Ligands Studied:  Pro-inflammatory cytokines